Volume 46, Issue 12 e14426
REVIEW

Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease

Surya Nath Pandey

Corresponding Author

Surya Nath Pandey

Department of Pharmacology, University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India

Department of Pharmacology, College of Pharmacy, Teerthanker Mahaveer University, Moradabad, UP, India

Correspondence

Surya Nath Pandey, Department of Pharmacology, University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.

Email: [email protected]; [email protected]

Search for more papers by this author
Gurfateh Singh

Gurfateh Singh

Department of Pharmacology, University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India

Search for more papers by this author
Bhupesh Chander Semwal

Bhupesh Chander Semwal

Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India

Search for more papers by this author
Gaurav Gupta

Gaurav Gupta

School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India

Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India

Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

Search for more papers by this author
Khalid Saad Alharbi

Khalid Saad Alharbi

Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia

Search for more papers by this author
Waleed Hassan Almalki

Waleed Hassan Almalki

Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia

Search for more papers by this author
Mohammed Albratty

Mohammed Albratty

Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia

Search for more papers by this author
Asim Najmi

Asim Najmi

Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia

Search for more papers by this author
Abdulkarim M. Meraya

Abdulkarim M. Meraya

Pharmacy Practice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia

Search for more papers by this author
First published: 28 September 2022
Citations: 17

Abstract

Alzheimer's disease (AD) is a neurological illness that causes memory loss over time. Currently, available pharmaceutical medicines and products are limited, and they have side effects at a higher price. Researchers and scientists have observed significant effects of nutraceuticals. Various preclinical and clinical studies were investigated for the Anti-Alzheimer's activity of nutraceuticals. The increasing ability of the pathogenesis of AD has led to the analysis of novel therapeutic targets, including the pathophysiological mechanisms and distinct cascades. So, current improvement will show the most adequate and prominent nutraceuticals and suggested concise mechanisms involving autophagy regulation, anti-inflammatory, antioxidant, mitochondrial homeostasis, and others. The effects of nutraceuticals cannot be ignored; it is important to investigate high-quality clinical trials. Given the potential of nutraceuticals to battle AD as multi-targeted therapies, it's vital to evaluate them as viable lead compounds for drug discovery and development. To the best of the authors ‘knowledge, modification of blood–brain barrier permeability, bioavailability, and aspects of randomized clinical trials should be considered in prospective investigations.

Practical applications

Advancements in molecular diagnostic and fundamentals have implemented particular usefulness for drug evaluation. An excess of experimental knowledge occurs regarding the effect of nutraceuticals on AD. There are various preclinical and clinical studies that have been done on nutraceuticals. In addition, various substitute inhibit and enhance some pathophysiological levels associated with AD. Nutraceuticals are easily available and have fewer side effects with cost-effective advantages. However, further investigations and clinical trials are required to encourage its effect on disease.

CONFLICT OF INTEREST

None.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.